SCHEMBL6408009

SCHEMBL6408009

O=C(CC(C(=O)O)c1ccc(CBr)cc1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
CES2 O00748 1/20 0.53
CES1 P23141 1/20 0.53
POLB P06746 3/20 0.52
MAPT P10636 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TSHR P16473 1/20 0.50
PTPN1 P18031 1/20 0.46
GSK3B P49841 1/20 0.46
PKM P14618 1/20 0.46
GAA P10253 1/20 0.42
MAPK9 P45984 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1754732 0.85 KMT2A (0.71) CYP2C9CYP2C19KMT2AMEN1CES1
SCHEMBL8886254 0.81 CES2 (0.53) KMT2AMEN1CES2CES1POLB
SCHEMBL7821921 0.81 POLB (0.77) CYP2C9CYP2C19KMT2AMEN1POLB
SCHEMBL15075817 0.81 POLB (0.77) CYP2C9CYP2C19KMT2AMEN1POLB
SCHEMBL15075815 0.81 POLB (0.77) CYP2C9CYP2C19KMT2AMEN1POLB
SCHEMBL9148324 0.77 L3MBTL1 (0.73) CYP2C9CYP2C19KMT2AMEN1CES2
SCHEMBL9707099 0.77 CES2 (0.51) KMT2AMEN1CES2CES1POLB
SCHEMBL29110203 0.74 ALDH1A1 (0.50) CYP2C9CYP2C19KMT2AMEN1POLB
SCHEMBL728227 0.73 POLB (0.88) CYP2C9CYP2C19KMT2AMEN1POLB
SCHEMBL29110265 0.73 KMT2A (0.60) KMT2AMEN1POLBMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use TAKEDA CHEMICAL INDUSTRIES, LTD. 2005-02-17 US disclosed
EP-1460062-A1 NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use BDKRB1, BDKRB2, TACR1 CYP2C9 1127/4885CYP2C19 866/4885KMT2A 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.